Balkrishna Acharya, Bhattacharya Kunal, Samanta Himadri Sekhar, Tomer Meenu, Varshney Anurag
Drug Discovery and Development Division, Patanjali Research Foundation, Haridwar, 249 405, Uttarakhand, India.
Department of Allied and Applied Sciences, University of Patanjali, Patanjali Yog Peeth, Haridwar, 249 405, Uttarakhand, India.
Biol Trace Elem Res. 2025 Apr;203(4):2320-2338. doi: 10.1007/s12011-024-04304-3. Epub 2024 Jul 15.
Mandoor Bhasma (MB) medicine, based on classical Indian Ayurveda, was size- and surface-modified to improve its therapeutic efficiency for treating iron-deficient anemia. Physical grinding reduced the size of MB to the nanoparticle (nano-MB) range without changing its chemical composition, as measured by particle size distribution. The surface of nano-MB was modified with ascorbic acid (nano-AA-MB) and confirmed using scanning electron microscopy and Fourier transformed infrared spectroscopy. Enhanced iron dissolution from the surface-modified nano-AA-MB under neutral-to-alkaline pH conditions, and in the intestinal region of the simulated gastrointestinal tract (GIT) digestion model was determined using inductively coupled plasma mass spectroscopy. GIT digestae of MB microparticles and nano-AA-MB were found to be biocompatible in human colon epithelial (Caco-2) cells, with the latter showing threefold higher iron uptake. Subsequently, a dose-dependent increase in cellular ferritin protein was observed in the nano-AA-MB digestae-treated Caco-2 cells, indicating the enhanced bioavailability and storage of dissolved iron. Overall, the study showed that reducing the size of centuries-old traditional Mandoor Bhasma medicine to nanoscale, and its surface-modification with ascorbic acid would help in enhancing its therapeutic abilities for treating iron-deficient anemia.
基于古印度阿育吠陀医学的曼杜尔煅灰（MB）药物，在尺寸和表面进行了改性，以提高其治疗缺铁性贫血的疗效。通过粒度分布测量可知，物理研磨将MB的尺寸减小到了纳米颗粒（纳米MB）范围，且未改变其化学成分。纳米MB的表面用抗坏血酸进行了改性（纳米抗坏血酸-MB），并用扫描电子显微镜和傅里叶变换红外光谱进行了确认。使用电感耦合等离子体质谱法测定了在中性至碱性pH条件下以及在模拟胃肠道（GIT）消化模型的肠道区域中，表面改性的纳米抗坏血酸-MB中铁的溶解增强情况。发现MB微粒和纳米抗坏血酸-MB的GIT消化物在人结肠上皮（Caco-2）细胞中具有生物相容性，后者的铁摄取量高出三倍。随后，在纳米抗坏血酸-MB消化物处理的Caco-2细胞中观察到细胞铁蛋白蛋白呈剂量依赖性增加，这表明溶解铁的生物利用度和储存得到了增强。总体而言，该研究表明，将有着数百年历史的传统曼杜尔煅灰药物缩小到纳米级，并对其进行抗坏血酸表面改性，将有助于提高其治疗缺铁性贫血的治疗能力。
